DOCSLIB.ORG

Weekly Epidemiological Report Week 15: 12Th – 18Th April 2021 Highlight of the Week Nigeria Commemorates World Hand Hygiene Day

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Weekly Epidemiological Report Week 15: 12Th – 18Th April 2021 Highlight of the Week Nigeria Commemorates World Hand Hygiene Day Issue: Volume 12 No. 15. 4th May 2021 Nigeria Centre for Disease Control Protecting the health of Nigerians Weekly Epidemiological Report Week 15: 12th – 18th April 2021 Highlight of the Week Nigeria Commemorates World Hand Hygiene Day Globally, promotion of hand hygiene is one of the cost effective public health interventions for the prevention and control of infections, particularly those caused by epidemic-prone pathogens. In line with this, the World Health Organisation launched the World Hand Hygiene Day which is celebrated every year. This event is part of the global advocacy efforts to mobilise citizens around the world to imbibe a general culture of handwashing with soap and running water, and the use of alcohol-based hand sanitisers. The theme for this year’s event is “Achieving hand hygiene at the point of care” with the slogan “Seconds Save Lives – Clean Your Hands. In recognition of the importance of public awareness of hand hygiene, Nigeria joined the global community to commemorate the World Hand Hygiene Day on the 5thof May, 2021. The national sub- theme “One Nation, One Plan: Turn Nigeria Orange” is a recognition of the “Orange Network Project” which was launched by the Nigeria Centre for Disease Control (NCDC) in 2019. This is a network of tertiary health facilities in Nigeria which aims at promoting centers of excellence in infection prevention and control. As part of her activities to mark this year’s event, the NCDC in collaboration with the Federal Medical Centre, Abuja organised a lecture on the importance of hand hygiene in health care settings. This further highlighted the priority given to the safety of health care workers (HCWs) by the NCDC. Some of our key partners - Infection Control Africa Network, Nigeria Society for Infection Control, Dr. Ameyo Stella Adadevoh Health Trust (DRASA), Africa Centre for Disease Control (Africa CDC), the World Health Organisation (WHO)' etc. also lent their voices and encouraged all to take responsibility to promote hand hygiene with key messages as follows: 1. Health Care Workers: Now more than ever, clean your hands at the point of care! 2. Infection Prevention and Control (IPC) practitioners: Be a champion and mentor colleagues on clean hands at the point of care! 3. Facility Managers: Ensure hand hygiene supplies are available at every point of care! 4. Policymakers: Invest now to ensure hand hygiene for all! 5. Patients and families: Wash your hands regularly, clean hands save lives! 6. Vaccinators: Clean your hands with every vaccination! 7. Everyone: Make washing your hands a regular habit – it protects us all! An important outcome from this year’s event was the strong collaboration with stakeholders particularly in the area of IPC. We strongly believe that the afore-listed key messages when implemented will also contribute to the control of the ongoing COVID-19 outbreak in Nigeria. The NCDC remains committed to working closely with all relevant stakeholders in promoting hand hygiene- practices among HCWs and the public at large. Weekly Issue: Volume 12 No. 15. 4th May 2021 Epidemiological Report Summary of Incidents Ongoing incidents 1 Ongoing incidents are defined as confirmed cases where a national EOC or equivalent has been activated (EOC is currently activated for COVID-19) Other incidents are those with confirmed cases for which EOC is not activated Data Source: SITAware Weekly Issue: Volume 12 No. 15. 4th May 2021 Epidemiological Report Summary Week 15: 12th – 18th April 2021 Note: Coronavirus Disease is from outbreak onset till week 17 2021: 2nd May, 2021) Cerebrospinal Lassa Fever1,2 Yellow Fever3,4 Meningitis (CSM) 3,4 43 6 34 Suspected case(s) Suspected case(s) Suspected case(s) 6 1 0 Confirmed case(s) Confirmed case(s) Confirmed case(s) 0 0 0 Death(s) Death(s) Death(s) Cholera3,4 Measles3,4 Monkeypox1,4 166 629 1 Suspected case(s) Suspected case(s) Suspected case(s) 0 2 1 Confirmed case(s) Confirmed case(s) Confirmed case(s) 11 8 0 Death(s) Death(s) Death(s) Acute Flaccid National Sentinel Coronavirus Disease Paralysis (AFP) 3,4 influenza surveillance5 as at week 171, 56 398 1,939,165 Suspected case(s) Suspected case(s) Suspected case(s) 0 10 168,181 Confirmed case(s) Confirmed case(s) Confirmed case(s) 2,063 Death(s) Timeliness Completeness of reports3 of reports3 94.6% 97.3% Last 4 weeks Last 4 weeks 96.8% 98.7% Year to date Year to date Notes 1. Information for this disease was retrieved from the Technical Working Group and Situation Reports 2. Case Fatality Rate (CFR) for this disease is reported for confirmed cases only 3. Information for this disease was retrieved from IDSR 002 data 4. CFR for this disease is reported for total cases i.e. suspected + confirmed 5. Information for sentinel influenza was retrieved from the laboratory Weekly Issue: Volume 12 No. 15. 4th May 2021 Epidemiological Report Lassa Fever Week 15 Suspected Confirmed Number of States Deaths cases cases and LGAs affected State: 2 43 6 0 LGA: 3 Year to date (week 1 – 52) Suspected Confirmed Deaths CFR cases cases 2020 2021 2020 2021 2020 2021 2020 2021 4386 1595 973 247 188 50 19.3% 20.2% Figure 1: Number of suspected and confirmed Figure 2: Location of confirmed cases of cases of Lassa Fever, Nigeria, Weeks 1 – 52, Lassa Fever by State, Nigeria, week 15, 2021 2021 Key points ● There were 43 suspected cases, six were laboratory confirmed and no death was recorded from three LGAs in two states Actions To date: ● Conducted 2021 Lassa fever (LF) high burden states preparedness/response engagement meeting ● Dissemination of reviewed case management and safe burial practices guidelines ● Ensured all five LF molecular laboratories in the NCDC network are working at full capacity for timely testing of samples with reduced turnaround time Planned: ● Finalise LF five-year strategic plan Weekly Issue: Volume 12 No. 15. 4th May 2021 Epidemiological Report Cerebrospinal Meningitis (CSM) Week 15 Suspected Confirmed Number of States Deaths cases cases and LGAs affected State: 2 6 1 0 LGA: 3 Year to date (week 1 – 52) Suspected Confirmed Deaths CFR cases cases 2020 2021 2020 2021 2020 2021 2020 2021 222 93 0 6 3 0 1.4% 0% Figure 3: Number of suspected and confirmed Figure 4: Location of suspected cases of CSM by cases of CSM, Nigeria, weeks 1 – 52, 2021 State, Nigeria, week 15, 2021 Key points ● There were six suspected cases of Cerebrospinal Meningitis (CSM) reported from three LGAs in two states (Ebonyi – 1 & Katsina – 5). One was laboratory confirmed and no death was recorded Actions To date: ● National CSM TWG meets weekly to review reports from states and plan appropriately ● Enhanced surveillance in all states Planned: ● Continue harmonisation of the national line list and SORMAS data ● Continue to ensure that states reporting cases send their line lists and collect CSM samples Weekly Issue: Volume 12 No. 15. 4th May 2021 Epidemiological Report Yellow Fever Week 15 Suspected Confirmed Number of States Deaths cases cases and LGAs affected State: 13 + FCT 34 0 0 LGA: 25 Year to date (week 1 – 52) Suspected Confirmed Deaths CFR cases cases 2020 2021 2020 2021 2020 2021 2020 2021 695 393 6 0 0 0 0% 0% Figure 5: Number of suspected and Figure 6: Location of suspected cases of confirmed cases of Yellow Fever, Nigeria, Yellow Fever by States, Nigeria, week 15, weeks 1 – 52, 2021 2021 Key points ● There were 34 suspected cases of Yellow Fever (YF) reported from 25 LGAs in 13 states and FCT. None were laboratory confirmed and no death was recorded Actions To date: ● National YF multi-partner Technical Working Group (TWG) continues to coordinate activities across states. ● Daily monitoring and analysis of surveillance data across the country to guide response activities Planned: ● Continue supporting affected states across all pillars of response ● Continue harmonisation of surveillance and laboratory data ongoing Weekly Issue: Volume 12 No. 15. 4th May 2021 Epidemiological Report Cholera Week 15 Suspected Confirmed Number of States Deaths cases cases and LGAs affected State: 2 166 0 11 LGA: 10 Year to date (week 1 – 52) Suspected Confirmed Deaths CFR cases cases 2020 2021 2020 2021 2020 2021 2020 2021 749 *1397 0 5 31 *58 4.1% 4.2% *Outbreak data added to routine data Figure 7: Number of suspected and confirmed Figure 8: Location of suspected cases of cases of Cholera, Nigeria, weeks 1 – 52, 2021 Cholera by State, Nigeria, week 15, 2021 Key points ● There were 166 suspected cases of cholera reported from ten LGAs in two states (Bayelsa – 8 & Kano – 158). None were laboratory confirmed and eleven deaths were recorded Actions To date ● National Cholera Multi-Sectoral Technical Working Group (TWG) is monitoring all states and supporting affected states ● Developed the 2021 Annual Cholera Preparedness and Response Work plan ● Cholera jingles being aired in English and local languages across the country Planned: ● Continue follow up and monitoring of non-reporting states ● Build capacity for sample collection, transportation, and laboratory diagnosis across states Weekly Issue: Volume 12 No. 15. 4th May 2021 Epidemiological Report Measles Week 15 Suspected Confirmed Number of States and Deaths cases cases LGAs affected State: 21 + FCT 629 2 8 LGA: 92 Year to date (week 1 – 52) Suspected Confirmed Deaths CFR cases cases 2020 2021 2020 2021 2020 2021 2020 2021 11574 4679 636 64 45 17 0.4% 0.4% Figure 9: Number of suspected and confirmed Figure 10: Location of suspected cases of cases of Measles, Nigeria, weeks 1 – 52, 2021 Measles by State, Nigeria, week 15, 2021 Key points ● There were 629 suspected cases of measles reported from 92 LGAs in 21 states and FCT.
Load more

Recommended publications
  • Uveal Involvement in Marburg Virus Disease B
    Br J Ophthalmol: first published as 10.1136/bjo.61.4.265 on 1 April 1977. Downloaded from British Journal of Ophthalmology, 1977, 61, 265-266 Uveal involvement in Marburg virus disease B. S. KUMING AND N. KOKORIS From the Department of Ophthalmology, Johannesburg General Hospital and University of the Witwatersrand SUMMARY The first reported case of uveal involvement in Marburg virus disease is described. 'Ex Africa semper aliquid novi'. Two outbreaks of Marburg virus disease have been Rhodesia and had also been constantly at his documented. The first occurred in Marburg and bedside till his death. Lassa fever was suspected and Frankfurt, West Germany, in 1967 (Martini, 1969) she was given a unit of Lassa fever convalescent and the second in Johannesburg in 1975 (Gear, serum when she became desperately ill on the fifth 1975). This case report describes the third patient day. She also developed acute pancreatitis. Within in the Johannesburg outbreak, who developed an 52 hours she made a dramatic and uneventful anterior uveitis. The cause of the uveitis was proved recovery. Her illness mainly affected the haema- to be the Marburg virus by identiying it in a tissue topoietic, hepatic, and pancreatic systems. culture of her aqueous fluid. The subject of this report was a nurse who had helped to nurse patients 1 and 2. Nine days after the Case report death ofthe first patient she presented with lower back pain and high fever. She developed hepatitis, a mild Before describing the case history of the patient the disseminated intravascular coagulation syndrome, events leading to her contracting the disease must successfully treated with heparin, and the classical be briefly described.
    [Show full text]
  • Chikungunya Fever: Epidemiology, Clinical Syndrome, Pathogenesis
    Antiviral Research 99 (2013) 345–370 Contents lists available at SciVerse ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy ⇑ Simon-Djamel Thiberville a,b, , Nanikaly Moyen a,b, Laurence Dupuis-Maguiraga c,d, Antoine Nougairede a,b, Ernest A. Gould a,b, Pierre Roques c,d, Xavier de Lamballerie a,b a UMR_D 190 ‘‘Emergence des Pathologies Virales’’ (Aix-Marseille Univ. IRD French Institute of Research for Development EHESP French School of Public Health), Marseille, France b University Hospital Institute for Infectious Disease and Tropical Medicine, Marseille, France c CEA, Division of Immuno-Virologie, Institute of Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses, France d UMR E1, University Paris Sud 11, Orsay, France article info abstract Article history: Chikungunya virus (CHIKV) is the aetiological agent of the mosquito-borne disease chikungunya fever, a Received 7 April 2013 debilitating arthritic disease that, during the past 7 years, has caused immeasurable morbidity and some Revised 21 May 2013 mortality in humans, including newborn babies, following its emergence and dispersal out of Africa to the Accepted 18 June 2013 Indian Ocean islands and Asia. Since the first reports of its existence in Africa in the 1950s, more than Available online 28 June 2013 1500 scientific publications on the different aspects of the disease and its causative agent have been pro- duced. Analysis of these publications shows that, following a number of studies in the 1960s and 1970s, Keywords: and in the absence of autochthonous cases in developed countries, the interest of the scientific commu- Chikungunya virus nity remained low.
    [Show full text]
  • Viral Hemorrhagic Fevers and Bioterrorism
    What you need to know about . Viral Hemorrhagic Fevers and Bioterrorism What are viral hemorrhagic fevers? How are viral hemorrhagic fevers Viral hemorrhagic fevers (VHFs) are a spread? group of illnesses caused by several distinct In nature, viruses causing hemorrhagic fever families of viruses. In general the term typically are passed from mice, rats, fleas “viral hemorrhagic fever” describes severe and ticks to humans. People can be infected problems affecting several organ systems when they come in contact with urine, fecal in the body. Typically, the entire system of ma�er, saliva or other body fluids from blood vessels is damaged, and the body has infected rodents. Fleas and ticks transmit the problems regulating itself. Symptoms o�en viruses when they bite a person or when a include bleeding, but the bleeding itself is person crushes a tick. Hosts for some viruses rarely life-threatening. VHFs are caused by such as Ebola and Marburg are not known. viruses of four families: Some viruses such as Ebola, Marburg and Lassa can be spread from person to person • Arenavirus including Lassa fever and by direct contact with infected blood or Argentine, Bolivian, Brazilian and organs or indirectly through contact with Venezuelan hemorrhagic fevers; objects such as syringes or needles that are • Filovirus including Ebola and Marburg; contaminated with infected body fluids. • Bunyavirus including Hantavirus and Ri� Valley Fever; What are the symptoms? • Flavivirus including yellow fever and Symptoms vary with the different virus dengue fever. families, but first signs o�en include sudden fever, weakness, muscle pain, tiredness, Can viral hemorrhagic fevers be used headache and sore throat.
    [Show full text]
  • Viral Hemorrhagic Fevers (Lassa, Marburg, Ebola, Crimean-Congo, and Other Emerging Viruses)
    Viral Hemorrhagic Fevers (Lassa, Marburg, Ebola, Crimean-Congo, and other emerging viruses) What Are They? Viral hemorrhagic fevers are a group of illnesses causes by several viruses. These viruses affect multiple organs in the body by damaging the vascular (blood vessel) system. The bleeding or hemorrhaging caused by the virus is not usually life threatening but damage to organ systems in the body can range from mild to deadly. The viruses responsible for this type of illness include Lassa, Marburg, Ebola, and Crimean-Congo hemorrhagic fever. How can you get it? These emerging viral hemorrhagic fevers are presumed to be animal borne (zoonotic) and can be transmitted to humans through contact. Infected humans can spread the virus to each other through contact with contaminated objects or blood. The risk of acquiring these diseases is typically restricted to the geographic regions where the virus is found. Given global travel, rare cases have been reported outside of the host region. These rare cases are probably the greatest form of the occupational threat to fire fighters. Lassa Associated with specific rodents Found in West Africa Marburg Transmitted by African fruit bat Found in Africa Ebola Transmitted by unknown animal Found in Africa Crimean-Congo Tick-borne virus Found in Africa, Asia, Europe What are the symptoms? The time to develop symptoms varies by virus but is between 2 to 21 days after exposure to the Ebola virus. The signs and symptoms of viral hemorrhagic fever vary depending on the virus but include: Flu-like symptoms o Fever o Fatigue o Muscle aches Exhaustion Nausea and/or vomiting Abdominal pain Shock Seizures Delirium Bleeding Organ failure The most common complication of Lassa fever is deafness.
    [Show full text]
  • 1 Lujo Viral Hemorrhagic Fever: Considering Diagnostic Capacity And
    1 Lujo Viral Hemorrhagic Fever: Considering Diagnostic Capacity and 2 Preparedness in the Wake of Recent Ebola and Zika Virus Outbreaks 3 4 Dr Edgar Simulundu1,, Prof Aaron S Mweene1, Dr Katendi Changula1, Dr Mwaka 5 Monze2, Dr Elizabeth Chizema3, Dr Peter Mwaba3, Prof Ayato Takada1,4,5, Prof 6 Guiseppe Ippolito6, Dr Francis Kasolo7, Prof Alimuddin Zumla8,9, Dr Matthew Bates 7 8,9,10* 8 9 1 Department of Disease Control, School of Veterinary Medicine, University of Zambia, 10 Lusaka, Zambia 11 2 University Teaching Hospital & National Virology Reference Laboratory, Lusaka, Zambia 12 3 Ministry of Health, Republic of Zambia 13 4 Division of Global Epidemiology, Hokkaido University Research Center for Zoonosis 14 Control, Sapporo, Japan 15 5 Global Institution for Collaborative Research and Education, Hokkaido University, Sapporo, 16 Japan 17 6 Lazzaro Spallanzani National Institute for Infectious Diseases, IRCCS, Rome, Italy 18 7 World Health Organization, WHO Africa, Brazzaville, Republic of Congo 19 8 Department of Infection, Division of Infection and Immunity, University College London, 20 U.K 21 9 University of Zambia – University College London Research & Training Programme 22 (www.unza-uclms.org), University Teaching Hospital, Lusaka, Zambia 23 10 HerpeZ (www.herpez.org), University Teaching Hospital, Lusaka, Zambia 24 25 *Corresponding author: Dr. Matthew Bates 26 Address: UNZA-UCLMS Research & Training Programme, University Teaching Hospital, 27 Lusaka, Zambia, RW1X 1 28 Email: [email protected]; Phone: +260974044708 29 30 2 31 Abstract 32 Lujo virus is a novel old world arenavirus identified in Southern Africa in 2008 as the 33 cause of a viral hemorrhagic fever (VHF) characterized by nosocomial transmission 34 with a high case fatality rate of 80% (4/5 cases).
    [Show full text]
  • Orthohantaviruses Belonging to Three Phylogroups All Inhibit Apoptosis in Infected Target Cells
    www.nature.com/scientificreports OPEN Orthohantaviruses belonging to three phylogroups all inhibit apoptosis in infected target cells Received: 13 July 2018 Carles Solà-Riera1, Shawon Gupta1,2, Hans-Gustaf Ljunggren1 & Jonas Klingström 1 Accepted: 3 December 2018 Orthohantaviruses, previously known as hantaviruses, are zoonotic viruses that can cause hantavirus Published: xx xx xxxx pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS) in humans. The HPS-causing Andes virus (ANDV) and the HFRS-causing Hantaan virus (HTNV) have anti-apoptotic efects. To investigate if this represents a general feature of orthohantaviruses, we analysed the capacity of six diferent orthohantaviruses – belonging to three distinct phylogroups and representing both pathogenic and non-pathogenic viruses – to inhibit apoptosis in infected cells. Primary human endothelial cells were infected with ANDV, HTNV, the HFRS-causing Puumala virus (PUUV) and Seoul virus, as well as the putative non-pathogenic Prospect Hill virus and Tula virus. Infected cells were then exposed to the apoptosis-inducing chemical staurosporine or to activated human NK cells exhibiting a high cytotoxic potential. Strikingly, all orthohantaviruses inhibited apoptosis in both settings. Moreover, we show that the nucleocapsid (N) protein from all examined orthohantaviruses are potential targets for caspase-3 and granzyme B. Recombinant N protein from ANDV, PUUV and the HFRS-causing Dobrava virus strongly inhibited granzyme B activity and also, to certain extent, caspase-3 activity. Taken together, this study demonstrates that six diferent orthohantaviruses inhibit apoptosis, suggesting this to be a general feature of orthohantaviruses likely serving as a mechanism of viral immune evasion. Orthohantaviruses, of the order Bunyavirales and previously known as hantaviruses, are small single-stranded negative-sense RNA viruses with a tri-segmented genome (S, M and L segments) encoding four to fve proteins.
    [Show full text]
  • Ebola Virus Disease and Clinical Care Part I: History, Transmission, and Clinical Presentation
    Ebola Virus Disease and Clinical Care Part I: History, Transmission, and Clinical Presentation This lecture is on Ebola virus disease (EVD) and clinical care. This is part one of a three-part lecture on this topic. Preparing Healthcare Workers to Work in Ebola Treatment Units (ETUs) in Africa This lecture will focus on EVD in the West African setting. Ebola Virus Disease and Clinical Care: The training and information you receive in this course will Part I: History, Transmission, and Clinical not cover the use of certain interventions such as intubation Presentation or dialysis which are not available in West African Ebola Treatment Units (ETUs). You will need supplemental training This presentation is current as of December 2014. This presentation contains materials from Centers for Disease Control and to care for patients appropriately in countries where advanced Prevention (CDC), Médecins Sans Frontières (MSF), and World Health Organization (WHO). care is available. U.S. Department of Health and Human Services U.S. Department of Health and Human Services Centers for Disease Control and Prevention Centers for Disease Control and Prevention version 12.03.2014 The learning objectives for this lecture are to: Learning Objectives ▶ Describe the routes of Ebola virus transmission Describe the routes of Ebola virus transmission Explain when and how patients are infectious ▶ Explain when and how patients are infectious Describe the clinical features of patients with Ebola ▶ Describe screening criteria for Ebola virus disease Describe the clinical features of patients with Ebola (EVD) used in West Africa Explain how to identify patients with suspected ▶ Describe screening criteria for EVD used in West Africa EVD who present to the ETU ▶ Explain how to identify patients with suspected EVD who present to the ETU This presentation contains materials from CDC, MSF, and WHO 2 A number of different viruses cause viral hemorrhagic fever.
    [Show full text]
  • Mapping the Risk and Distribution of Epidemics in the WHO African Region
    Mapping the Risk and Distribution of Epidemics in the WHO African Region A Technical Report May 2016 WHO/AFRO Library Cataloguing – in – Publication Data Mapping the Risk and Distribution of Epidemics in the WHO African Region: a technical report 1. Disease Outbreaks – statistics and numerical data 2. Epidemics – statistics and numerical data 3. Communicable Diseases – statistics and numerical data 4. Risk Assessment – supply and distribution – statistics and numerical data 5. Data collection – utilization 6. Africa I. Work Health Organization. Regional Office for Africa II. Title ISBN: 978-9290233084-4 (NLM Classification : WA 105) © WHO Regional Office for Africa, 2016 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved. Copies of this publication may be obtained from the Library, WHO Regional Office for Africa, P.O. Box 6, Brazzaville, Republic of Congo (Tel: +47 241 39100; Fax: +47 241 39507; E-mail: [email protected]). Requests for permission to reproduce or translate this publication – whether for sale or for non-commercial distribution – should be sent to the same address. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Human Monkeypox in Sierra Leone After 44-Year Absence Of
    RESEARCH LETTERS Acknowledgments Human Monkeypox in We thank Linda Northrup for English editing. We thank the patient for consenting to publication of her clinical data. Sierra Leone after 44-Year Absence of Reported Cases About the Author Dr. Amsilli is an infectious and tropical diseases physician. Mary G. Reynolds, Nadia Wauquier, Yu Li, Her research interests are emerging infectious diseases and Panayampalli Subbian Satheshkumar, medicine quality. Lansana D. Kanneh, Benjamin Monroe, Jacob Maikere, Gbessay Saffa, Jean-Paul Gonzalez, Joseph Fair, References 1. Barutta L, Ferrigno D, Melchio R, Borretta V, Bracco C, Darin S. Carroll, Amara Jambai, Foday Dafae, Brignone C, et al. Hepatic brucelloma. Lancet Infect Dis. Sheik Humarr Khan, Lina M. Moses 2013;13:987–93. http://dx.doi.org/10.1016/S1473-3099 Author affiliations: Centers for Disease Control and Prevention, (13)70197-X 2. Franco MP, Mulder M, Gilman RH, Smits HL. Human Atlanta, Georgia, USA (M.G. Reynolds, Y. Li, P.S. Satheshkumar, brucellosis. Lancet Infect Dis. 2007;7:775–86. http://dx.doi.org/ B. Monroe, D.S. Carroll); MRI Global–Global Health Surveillance 10.1016/S1473-3099(07)70286-4 and Diagnostics, Gaithersburg, Maryland, USA (N. Wauquier); 3. Ariza J, Pigrau C, Cañas C, Marrón A, Martínez F, Almirante B, Kenema Government Hospital, Kenema, Sierra Leone et al. Current understanding and management of chronic hepatosplenic suppurative brucellosis. Clin Infect Dis. (L.D. Kanneh, S.H. Khan); Médecins Sans Frontières, Brussels, 2001;32:1024–33. http://dx.doi.org/10.1086/319608 Belgium (J. Maikere); Ministry of Health and Sanitation, Bo, 4. Santé Publique France, Institut National de Veille Sanitaire.
    [Show full text]
  • Systematic Review of Important Viral Diseases in Africa in Light of the ‘One Health’ Concept
    pathogens Article Systematic Review of Important Viral Diseases in Africa in Light of the ‘One Health’ Concept Ravendra P. Chauhan 1 , Zelalem G. Dessie 2,3 , Ayman Noreddin 4,5 and Mohamed E. El Zowalaty 4,6,7,* 1 School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa; [email protected] 2 School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Durban 4001, South Africa; [email protected] 3 Department of Statistics, College of Science, Bahir Dar University, Bahir Dar 6000, Ethiopia 4 Infectious Diseases and Anti-Infective Therapy Research Group, Sharjah Medical Research Institute and College of Pharmacy, University of Sharjah, Sharjah 27272, UAE; [email protected] 5 Department of Medicine, School of Medicine, University of California, Irvine, CA 92868, USA 6 Zoonosis Science Center, Department of Medical Biochemistry and Microbiology, Uppsala University, SE 75185 Uppsala, Sweden 7 Division of Virology, Department of Infectious Diseases and St. Jude Center of Excellence for Influenza Research and Surveillance (CEIRS), St Jude Children Research Hospital, Memphis, TN 38105, USA * Correspondence: [email protected] Received: 17 February 2020; Accepted: 7 April 2020; Published: 20 April 2020 Abstract: Emerging and re-emerging viral diseases are of great public health concern. The recent emergence of Severe Acute Respiratory Syndrome (SARS) related coronavirus (SARS-CoV-2) in December 2019 in China, which causes COVID-19 disease in humans, and its current spread to several countries, leading to the first pandemic in history to be caused by a coronavirus, highlights the significance of zoonotic viral diseases.
    [Show full text]
  • A Comparative Analysis of the West African Hemorrhagic Fevers Caused by the Lassa and Ebola Viruses Emiene E
    Southeastern University FireScholars Selected Honors Theses Spring 4-28-2017 A Comparative Analysis of the West African Hemorrhagic Fevers Caused by the Lassa and Ebola Viruses Emiene E. Amali-Adekwu Southeastern University - Lakeland Follow this and additional works at: http://firescholars.seu.edu/honors Part of the Immune System Diseases Commons, Immunology of Infectious Disease Commons, Immunopathology Commons, Infectious Disease Commons, and the Virus Diseases Commons Recommended Citation Amali-Adekwu, Emiene E., "A Comparative Analysis of the West African Hemorrhagic Fevers Caused by the Lassa and Ebola Viruses" (2017). Selected Honors Theses. 70. http://firescholars.seu.edu/honors/70 This Thesis is brought to you for free and open access by FireScholars. It has been accepted for inclusion in Selected Honors Theses by an authorized administrator of FireScholars. For more information, please contact [email protected]. A COMPARATIVE ANALYSIS OF THE WEST AFRICAN HEMORRHAGIC FEVERS CAUSED BY THE LASSA AND EBOLA VIRUSES By Emiene E. Amali-Adekwu Submitted to the Honors Program Committee in partial fulfillment of the requirements for University Honors Scholars Southeastern University 2017 Amali-Adekwu 1 ©Copyright, Emiene E. Amali-Adekwu 2017 Amali-Adekwu 2 Abstract Lassa fever (LF) and Ebola Hemorrhagic Fever (EHF) are viral diseases endemic to West Africa.The etiological agent of Lassa fever is an enveloped virus from the Arenaviridae family ​ and was first discovered in 1969 when two missionary nurses died of a mysterious illness in the town of Lassa in Borno state, Nigeria.1 This virus is animal-borne (zoonotic) and is carried by ​ the animal vector Mastomys natalensis (multimammate rat).
    [Show full text]
  • Emerging Viruses and Current Strategies for Vaccine Intervention
    doi: 10.1111/cei.13295 VACCINES FOR EMERGING PATHOGENS: FROM RESEARCH TO THE CLINIC. PART 1 Clinical and Experimental Immunology ReVieW ArTicLe Series Editor: E Diane Williamson Emerging viruses and current strategies for vaccine intervention OTHER ARTICLES PUBLISHED IN THIS REVIEW SERIES Vaccines for emerging pathogens: from research to the clinic. Clinical and Experimental Immunology 2019, 196: 155-156. HLA-E: exploiting pathogen-host interactions for vaccine development. Clinical and Experimental Immunology 2019, 196: 167-177. Novel multi-component vaccine approaches for Burkholderia pseudomallei. Clinical and Experimental Immunology 2019, 196: 178-188. Novel approaches for the design, delivery and administration of vaccine technologies. Clinical and Experimental Immunology 2019, 196: 189-204. Mucosal vaccines and technology. Clinical and Experimental Immunology 2019, 196: 205-214. Vaccines for emerging pathogens: prospects for licensure. Clinical and Experimental Immunology 2019, doi: 10.1111/cei.13284 B. Afrough, S. Dowall and Summary R. Hewson During the past decade several notable viruses have suddenly emerged Virology and Pathogenesis Laboratory, National Infection Service, Public Health from obscurity or anonymity to become serious global health threats, England, Salisbury, UK. provoking concern regarding their sustained epidemic transmission in immunologically naive human populations. With each new threat comes the call for rapid vaccine development. Indeed, vaccines are considered a critical component of disease prevention for
    [Show full text]